Sarepta Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300IKDPIED8J8IG21 - ISIN
US8036071004 (SRPT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€5.16 288.5% overvalued - Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. Read full profile
Fundamentals
- Net revenue
€2.12B - Gross margin
78.4% - EBIT
-€794.95K - EBIT margin
-0.0% - Net income
-€49.43M - Net margin
-2.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | May 6, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Ray Dalio |
|
|
|
Buy |